Drug Profile
Cannabidiol - Leaf Vertical
Alternative Names: bioRenovate CX; BRCX014Latest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Leaf Vertical
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Small molecules
- Mechanism of Action 5-HT1 serotonin receptor modulators; Antioxidants; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Transient receptor potential channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Basal cell cancer; Cancer; Glioblastoma; Multiple myeloma; Squamous cell cancer
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Basal-cell-cancer in USA (Sublingual)
- 28 Jul 2022 No recent reports of development identified for preclinical development in Glioblastoma in USA (Sublingual)
- 28 Jul 2022 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Sublingual)